Says continues to invest in R&D at “competitive levels.” Says plans to continue to increase dividend annually. Expects Innovative Medicine sales growth “slightly stronger” in 1H24 vs. 2H24. Expects FY24 MedTech operational sales growth “relatively consistent” throughout the year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JNJ:
- Johnson & Johnson (NYSE:JNJ) Drops Despite Q4 Beat
- Options Volatility and Implied Earnings Moves Today, January 23, 2024
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits
- Options Volatility and Implied Earnings Moves This Week, January 22 – January 26, 2024
- JNJ Earnings this Week: How Will it Perform?